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Abstract
Background: Most patients with chronic obstructive pulmonary disease (COPD) receive inhaled long-acting bronchodilators
and inhaled corticosteroids. Conventional meta-analyses established that these drugs reduce COPD exacerbations when
separately compared with placebo. However, there are relatively few head-to-head comparisons and conventional meta-analyses
focus on single comparisons rather than on a simultaneous analysis of competing drug regimens that would allow rank ordering
of their effectiveness. Therefore we assessed, using a network meta-analytic technique, the relative effectiveness of the common
inhaled drug regimes used to reduce exacerbations in patients with COPD.
Methods:  We conducted a systematic review and searched existing systematic reviews and electronic databases for
randomized trials of ≥ 4 weeks' duration that assessed the effectiveness of inhaled drug regimes on exacerbations in patients
with stable COPD. We extracted participants and intervention characteristics from included trials and assessed their
methodological quality. For each treatment group we registered the proportion of patients with ≥ 1 exacerbation during follow-
up. We used treatment-arm based logistic regression analysis to estimate the absolute and relative effects of inhaled drug
treatments while preserving randomization within trials.
Results: We identified 35 trials enrolling 26,786 patients with COPD of whom 27% had ≥ 1 exacerbation. All regimes reduced
exacerbations statistically significantly compared with placebo (odds ratios ranging from 0.71 (95% confidence interval [CI] 0.64
to 0.80) for long-acting anticholinergics to 0.78 (95% CI 0.70 to 0.86) for inhaled corticosteroids). Compared with long-acting
bronchodilators alone, combined treatment was not more effective (comparison with long-acting beta-agonists: odds ratio 0.93
[95% CI 0.84 to 1.04] and comparison with long-acting anticholinergics: odds ratio 1.02 [95% CI 0.90 to 1.16], respectively). If
FEV1  was  ≤ 40% predicted, long-acting anticholinergics, inhaled corticosteroids, and combination treatment reduced
exacerbations significantly compared with long-acting beta-agonists alone, but not if FEV1 was > 40% predicted. This effect
modification was significant for inhaled corticosteroids (P = 0.02 for interaction) and combination treatment (P = 0.01) but not
for long-acting anticholinergics (P = 0.46). A limitation of this analysis is its exclusive focus on exacerbations and lack of FEV1
data for individual patients.
Conclusion:  We found no evidence that one single inhaled drug regimen is more effective than another in reducing
exacerbations. Inhaled corticosteroids when added to long-acting beta-agonists reduce exacerbations only in patients with
COPD with FEV1 ≤ 40%.
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Background
Chronic obstructive pulmonary disease (COPD) has
become a leading cause of death worldwide and its man-
agement requires an enormous amount of human and
financial resources [1,2]. Reduction of exacerbation rates
is one of the main treatment goals in COPD management
since exacerbations bear heavily on the patient's health-
related quality of life and prognosis as well as on COPD-
related costs [3]. Several conventional meta-analyses pro-
vided evidence that long-acting beta-agonists, long-acting
anticholinergics and inhaled corticosteroids reduce exac-
erbations in patients with COPD when compared with
placebo [4-6]. The conventional meta-analyses are, how-
ever, less informative about the comparative effectiveness
of long-acting beta-agonists and anticholinergics or about
the additional value of inhaled corticosteroids when
added to long-acting bronchodilators. The comparative
effectiveness is of great interest to physicians because the
predominant question in clinical practice is to choose
between treatments rather than deciding whether to treat
or not to treat [7,8].
Opinions differ about whether a long-acting bronchodila-
tor alone is sufficient or if an inhaled corticosteroid pro-
vides additional benefits at least for some patients
[3,9,10]. Any added benefit of corticosteroids, if present,
should outweigh the associated risk for adverse effects and
their additional costs. Conventional meta-analyses [4-
6,11,12] do not provide enough support to solve this
debate because evidence from randomized head-to-head
comparisons is often unavailable. Also, conventional
meta-analyses cannot provide effect estimates for compar-
isons of more than two treatments at the same time, so
that a ranking of competing treatments is not available.
Finally, conventional meta-analyses cannot assess sub-
group effects reliably [13] although such information is
very valuable for clinicians. Theoretically, a single very
large trial would overcome these three limitations of con-
ventional meta-analysis. However, the sample size would
need to be a multiple of that of the recently published
TORCH trial [14] (more than 6000 patients) if subgroup
effects were to be investigated.
Since such a trial is very unlikely to become available, a
network meta-analysis or individual patient data meta-
analysis can be very informative [15]. Such pooled analy-
ses unify evidence from all randomized trials while fully
preserving randomization [16-18]. Therefore, our aim was
to assess the relative effectiveness of competing inhaled
drug regimens for the prevention of exacerbations in
patients with stable COPD in a pooled analysis of rand-
omized comparisons. In addition, we assessed whether
the effectiveness depend on the severity of COPD, treat-
ment duration, or the definition of an exacerbation (event
based or symptom based).
Methods
Data sources and selection
We searched the Cochrane Database of Systematic
Reviews (Oxford, United Kingdom, 2007, Issue 2), the
Database of Abstracts of Reviews of Effects (last search on
November 20th 2007) and the Health Technology Assess-
ment database (last search November on 20th 2007) for
randomized trials included in existing systematic reviews
(see Additional file 1 for systematic reviews used to iden-
tify relevant studies). We based our searches on existing
systematic reviews in order to avoid unnecessary duplica-
tion of previous work. The existing systematic reviews
used extensive search strategies that included several data-
bases such as Medline, EMBASE, CINAHL and LILACS as
well as websites of regulatory bodies. In addition, drug
companies were approached for unpublished trials. We
complemented these searches by entering all included
studies into the 'related articles' function of PubMed (last
search for trials on November 20th, 2007).
We included randomized trials without any language
restrictions that were ≥ 4 weeks in duration, included
patients with stable COPD, and assessed the effects of
long-acting beta-agonists, long-acting anticholinergics,
inhaled corticosteroids, or combination treatment (long-
acting beta-agonists plus inhaled corticosteroids) on exac-
erbations with or without placebo control. We included
all trials where the proportion of patients with at least one
exacerbation during follow-up was reported. We did not
include trials where only the mean number of exacerba-
tions per patient year was reported because meta-analysis
of such data is prone to bias without individual patient
data [19].
We retrieved all full reports of potentially eligible trials.
Two reviewers (research fellows with medical doctor
degrees and one and three years of research experience,
respectively) independently assessed them and deter-
mined their inclusion or exclusion. If the two reviewers
disagreed even after discussion, a third reviewer (epidemi-
ologist with MD and PhD degree) arbitrated. Out of 56 tri-
als identified initially, we excluded 20 (Figure 1, see also
Additional file 2 for excluded studies). Another trial met
the inclusion criteria but it could not be included in the
analysis because the treatments (combination of long-act-
ing beta-agonist, long-acting anticholinergic and inhaled
corticosteroid versus one or two components), were dis-
similar to those in the included trials [20]. We included
the remaining 35 randomized trials in the analysis [14,21-
54]. One trial [35] was republished together with another
trial [24]. We considered the data from both trials as pub-
lished in the second report [24].BMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Study flow from database searches to inclusion oftrials Figure 1
Study flow from database searches to inclusion oftrials. 40 trials were excluded after title and abstract screening 
because they obviously did not fulfill the inclusion criteria (not patients with COPD, patients with unstable COPD, short-acting 
bronchodilators, treatment duration < 4 weeks, no exacerbations ascertained). Reasons for exclusion for the 20 studies 
excluded after full text assessment are listed in Additional file 2.BMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Data extraction
We focused our analysis on exacerbations. For each trial
arm (2 to 4, depending on the trial), one reviewer
extracted the number of patients with at least one exacer-
bation during follow-up and the number of patients with
no exacerbation during follow-up (2 × 2, 3 × 2, or 4 × 2
tables). A second and, in case of disagreement, third
reviewer, checked the data extraction for correctness. We
also recorded whether the studies' definition of exacerba-
tion was event based (physician or emergency room visit,
hospital admission) or symptom based (increase of dysp-
nea, sputum, or cough; for example according to
Anthonisen et al [55]) and recorded the severity of exacer-
bation according to the Operational Classification of
Severity of the European Respiratory and American Tho-
racic Societies (severe or mild to moderate exacerbation
defined as requiring inpatient treatment or outpatient
treatment, respectively) [9]. We recorded the drugs that
were evaluated and classified them into the categories of
placebo, long-acting beta-agonists (salmeterol, formot-
erol), long-acting anticholinergics (tiotropium bromide),
and inhaled corticosteroids (budesonide, fluticasone, flu-
nisolide, or beclomethasone), or combined treatment
with a long-acting beta-agonist and an inhaled corticoster-
oid. Finally, we recorded treatment duration in weeks, the
patient group's mean age, and mean FEV1.
Study reporting quality assessment
For each trial, two reviewers independently evaluated the
quality of reporting for important components of internal
validity (Additional file 3). We assessed the method of
randomization, concealment of random allocation and
whether inclusion criteria were specified in order to judge
whether confounding was controlled for by randomiza-
tion and/or restriction. We recorded blinding of treatment
providers and patients to judge the presence of informa-
tion bias and we recorded whether an intention-to-treat
analysis was reported to assess if randomization was
maintained throughout the analyses. We resolved dis-
cordant scores based on real differences in interpretation
through consensus or third party arbitration. We used the
quality assessment to judge the validity of the trial results.
Data synthesis and analysis
Based on 2 × 2 tables from each study (or 3 × 2 and 4 × 2
tables, respectively), we created as many data entries with
respective coding for treatment and exacerbation (yes/no)
as there were patients in the respective cell. For example,
in the study of Brusasco et al [24] there were 156 patients
in the placebo group with an exacerbation and 244
patients without an exacerbation, resulting in 156 (exacer-
bation = yes) and 244 (exacerbation = no) data entries for
the 400 patients with placebo. For each of these entries we
entered the mean age and FEV1  as covariates. For a
detailed description of creating such a data set, see Addi-
tional file 4.
We performed a logistic regression arm-level analysis with
the presence of exacerbation as dependent and the differ-
ent treatment options as independent variables. We
started with placebo treatment as the reference group fol-
lowed by identical analyses where long-acting beta-ago-
nists, long-acting anticholinergics and inhaled
corticosteroids, respectively, served as reference group to
which the other treatments were compared. To preserve
randomization within each trial, we included a dummy
variable for each of the studies. This dummy variable also
adjusted for differences in risk profiles and study setup
between trials. Second, we conducted stratified analyses to
assess whether treatment duration or follow-up, respec-
tively, disease severity (expressed by FEV1), or the defini-
tion of exacerbation influenced the (relative) treatment
effects. We performed separate analyses for trials with a
treatment duration of ≤ and > 6 months and≤and > 12
months, for trials with event- or symptom-based exacer-
bations, and for trials including patients with a mean
post-bronchodilator FEV1 of ≤ and > 40% and 50% pre-
dicted (where available). We did not select 35% predicted
as cut-off because there was only one trial [47] with such
a low mean FEV1. To assess effect modification formally,
we tested for interaction by introducing product terms
between predictor variables and treatments into the logis-
tic regression analysis. With a random coefficient model,
we investigated the presence of any additional variation of
the treatment effects due to differences across trials [56].
All analyses were conducted using STATA (STATA™ for
Windows, version 9, Stata Corp; College Station, TX).
Role of the funding source
This work was supported by the Swiss National Science
Foundation and The Helmut Horten Foundation. These
funding sources did not have any influence on the plan-
ning, conduct and reporting of this study.
Results
Study characteristics
Table 1 (parts A-E) shows the characteristics of the 35 tri-
als with 26,786 patients. Median sample size per trial was
545 (interquartile range, 253 to 976). On the patient
level, median treatment duration was 25 weeks (inter-
quartile range, 12 to 52), median age was 64 years (inter-
quartile range, 63 to 65), and median FEV1 42% predicted
(interquartile range, 40 to 46). A total of 26 trials (74%)
with 23,245 patients used an event-based definition for
exacerbations, and nine trials (26%) with 3541 patients
had a symptom-based definition. 7201 patients (27%)
suffered from at least one exacerbation. A total of 8312
patients received placebo (32 trials), 6357 received long-
acting beta-agonists (21 trials), 4764 received a long-act-BMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Table 1: Study characteristics
Part A
Study Population Inhaled drug 
treatment
Treatment 
duration (months)
Definition of 
exacerbation
Severity of 
exacerbation
Baumgartner et al 
2007 [48]
n = 433 (58% males)
Mean age in years: 63
Mean FEV1: 41% 
predicted
Group 1: Salmeterol 
42 μg bid
Group 2: Formoterol 
25 μg bid
Group 3: Placebo
3 Event-based Moderate and severe
Beeh et al 2006 [21] n = 1639 (76% males)
Mean age in years: 62
Mean FEV1: 45% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
3 Event-based Moderate and severe
Bourbeau et al 1998 
[22]
n = 79 (66% males)
Mean age in years: 66
Mean FEV1: 43% 
predicted
Group 1: Budesonide 
800 μg bid
Group 2: Placebo
6 Event-based Moderate and severe
Boyd et al 1997[23] n = 445 (79% males)
Mean age in years: 62
Mean FEV1: ≈65% 
predicted 
(only FEV1 in liters 
reported)
Group 1: Salmeterol 
50 μg bid
Group 2: Placebo
3.5 Event-based Moderate and severe
Briggs et al 2005[49] n = 653 (66% males)
Mean age in years: 64
Mean FEV1: 38% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Salmeterol 
50 μg bid
3 Symptom-based Moderate and severe
Brusasco et al 2003 
[24,35]
n = 1207 (76% males)
Mean age in years: 64
Mean FEV1: 38% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Salmeterol 
50 μg bid
Group3: Placebo
6 Symptom-based Moderate and severe
Burge et al 2000 [25] n = 742 (75% males)
Mean age in years: 64
Mean FEV1: 50% 
predicted
Group 1: Fluticasone 
500 μg bid
Group 2: Placebo
36 Event-based Moderate and severe
Calverley et al 2003 
[26]
n = 1465 (76% males)
Mean age in years: 63
Mean FEV1: 45% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Fluticasone 
500 μg bid
Group 3: Salmeterol 
50 μg bid + 
Fluticasone 500 μg bid
Group 4: Placebo
12 Event-based Moderate and severe
Part B
Calverley et al 2003 
[27]
n = 1022 (73% males)
Mean age in years: 64
Mean FEV1: 36% 
predicted
Group 1: Formoterol 
9 μg bid
Group 2: Budesonide 
400 μg bid
Group 3: Formoterol 
9 μg bid + Budesonide 
320 μg bid
Group 4: Placebo
12 Event-based Moderate and severeBMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Calverley et al 2003 
[28]
n = 78 (60% males)
Mean age in years: 65
Mean FEV1: 40% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
6 Event-based Moderate and severe
Calverley et al 2007 
[14]
n = 6112 (76% males)
Mean age in years: 65
Mean FEV1: 44% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Fluticasone 
500 μg bid
Group 3: Salmeterol 
50 μg bid + 
Fluticasone 500 μg bid
Group 4: Placebo
36 Event-based Severe
Campbell et al 2005 
[29]
n = 432 (67% males)
Mean age in years: 60
Mean FEV1: 54% 
predicted
Group 1: Formoterol 
9 μg bid
Group 2: Placebo
6 Event-based Moderate and severe
Casaburi et al 2002 
[50]
n = 921 (65% males)
Mean age in years: 65
Mean FEV1: 36% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
12 Symptom-based Moderate and severe
Celli et al 2003 [30] n = 824 (70% males)
Mean age in years: 64
Mean FEV1: 42% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Placebo
3 Event-based Moderate and severe
Chapman et al 2002 
[31]
n = 408 (64% males)
Mean age: not 
reported
Mean FEV1: 45% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Placebo
5.5 Event-based Moderate and severe
Covelli et al 2004 [32] n = 196 (66% males)
Mean age in years: 65
Mean FEV1: 40% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
3 Symptom-based Moderate and severe
Part C
Dahl et al 2001 [33] n = 392 (75% males)
Mean age in years: 64
Mean FEV1: 45% 
predicted
Group 1: Formoterol 
24 μg bid
Group 2: Placebo
3 Event-based Severe
Dusser et al 2006 [34] n = 1010 (88% males)
Mean age in years: 65
Mean FEV1: 48% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
12 Event-based Moderate and severe
Hanania et al 2003 
[51]
n = 540 (63% males)
Mean age in years: 64
Mean FEV1: 42% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Fluticasone 
250 μg bid
Group 3: Salmeterol 
50 μg bid + 
Fluticasone 250 μg bid
Group 4: Placebo
5.5 Event-based Moderate and severe
Kardos et al 2007 [52] n = 994 (76% males)
Mean age in years: 64
Mean FEV1: 40% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Salmeterol 
50 μg bid + 
Fluticasone 500 μg bid
10 Event-based Moderate and severe
Table 1: Study characteristics (Continued)BMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Littner et al 2000 [36] n = 68 (65% males)
Mean age in years: 66
Mean FEV1: 42% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
1 Symptom-based Moderate and severe
Mahler et al 1999 [37] n = 278 (74% males)
Mean age in years: 63
Mean FEV1: 40% 
predicted
Group 1: Salmeterol 
42 μg bid
Group 2: Placebo
3 Symptom-based Moderate and severe
Mahler et al 2002 [38] n = 671 (66% males)
Mean age in years: 64
Mean FEV1: 41% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Fluticasone 
500 μg bid
Group 3: Salmeterol 
50 μg bid + 
Fluticasone 500 μg bid
Group 4: Placebo
5.5 Event-based Moderate and severe
Part D
Niewoehner et al 
2005 [39]
n = 1829 (99% males)
Mean age in years: 68
Mean FEV1: 36% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Placebo
6 Event-based Moderate and severe
Paggiaro et al 1998 
[40]
n = 281 (74% males)
Mean age in years: 63
Mean FEV1: 57% 
predicted
Group 1: Fluticasone 
500 μg bid
Group 2: Placebo
12 Event-based Moderate and severe
Paggiaro et al 2006 
[41]
n = 114 (73% males)
Mean age in years: 66
Mean FEV1: 53% 
predicted
Group 1: Flunisolide 
1 mg bid
Group 2: Placebo
6 Event-based Moderate and severe
Rossi 2002[42] n = 434 (84% males)
Mean age in years: 63
Mean FEV1: 47% 
predicted
Group 1: Formoterol 
25 μg bid
Group 2: Placebo
3 Event-based Moderate and severe
Stockley et al 2006 
[43]
n = 634 (76% males)
Mean age in years: 62
Mean FEV1: 46% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Placebo
12 Event-based Moderate and severe
Szafranski et al 2000 
[44]
n = 812 (79% males)
Mean age in years: 64
Mean FEV1: 36% 
predicted
Group 1: Formoterol 
4.5 μg bid
Group 2: Budesonide 
200 μg bid
Group 3: Formoterol 
4.5 μg bid + 
Budesonide 160 μg 
bid
Group 4: Placebo
12 Event-based Moderate and severe
Van der Valk et al 
2002 [45]
n = 244 (84% males)
Mean age in years: 64
Mean FEV1: 57% 
predicted
Group 1: Fluticasone 
500 μg bid
Group 2: Placebo
5.5 Event-based Moderate and severe
Part E
Van Noord et al 2000 
[46]
n = 92 (88% males)
Mean age in years: 65
Mean FEV1: 41% 
predicted
Group 1: Salmeterol 
50 μg bid
Group 2: Placebo
3 Event-based Moderate and severe
Table 1: Study characteristics (Continued)BMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Wadbo et al 2002 
[47]
n = 121 (53% males)
Mean age in years: 64
Mean FEV1: 33% 
predicted
Group 1: Formoterol 
18 μg bid
Group 2: Placebo
3 Symptom-based Moderate and severe
Wedzicha et al 2008 
[53]
n = 1323 (83% males)
Mean age in years: 64
Mean FEV1: 39% 
predicted
Group 1: Tiotropium 
18 μg qd
Group 2: Salmeterol 
50 μg bid + 
Fluticasone 500 μg bid
24 Event-based Moderate and severe
Weir et al 1999 [54] n = 98 (72% males)
Mean age in years: 66
Mean FEV1: not 
reported
Group 1: 
Beclomethasone 750–
1000 μg bid
Group 2: Placebo
5.5 Symptom-based Moderate and severe
Table 1: Study characteristics (Continued)
ing anticholinergic (11 trials), 3492 an inhaled corticos-
teroid (12 trials), and 3861 patients combination
treatment (8 trials).
Quality of reporting
The median number of adequately reported aspects of
study quality was 4 out of 6 (interquartile range 3–5,
Additional file 1). This was largely influenced by the fre-
quent reporting of inclusion criteria and blinding (94.1%
of trials). However, the method of randomization
(35.3%), concealment of random allocation (29.4%) and
an intention to treat analysis (50.0%) were reported less
frequently.
Comparisons of inhaled drug regimes
All treatments significantly reduced exacerbations when
compared with placebo, with odds ratios ranging from
0.71 (95% confidence interval [CI] 0.64 to 0.80) for long-
acting anticholinergics to 0.78 (95% CI 0.70 to 0.86) for
inhaled corticosteroids (Figure 2). Comparing active
drugs among each other, we found no significant differ-
ences between long-acting beta-agonists, long-acting anti-
cholinergics, inhaled corticosteroids, and combination
treatment. In particular, there were no significant differ-
ences between long-acting beta-agonists and long-acting
anticholinergics (odds ratio, 0.91; 95% CI 0.81 to 1.03),
or between combination treatment and long-acting beta-
agonists (odds ratio, 0.93; 95% CI 0.84 to 1.04) or long-
acting anticholinergics alone (odds ratio 1.02; 95% CI
0.90 to 1.16).
When we analyzed patients with FEV1 ≤ 40% (n = 9,434,
mean FEV1 = 37% predicted), long-acting anticholinergics
(odds ratio 0.83; 95% CI 0.71 to 0.98), inhaled corticos-
teroids (odds ratio 0.75; 95% CI 0.57 to 1.00), and com-
bination treatment (odds ratio 0.79; 95% CI 0.67 to 0.93)
reduced exacerbations significantly compared with long-
acting beta-agonists alone (Figure 3). In patients with
FEV1 > 40% predicted (n = 17,352, mean FEV1 = 46% pre-
dicted), there were no differences between treatments.
Thus, the difference between point estimates in patients
with FEV1 ≤ or > 40% was small for long-acting anticholin-
ergics (0.09) but larger for inhaled corticosteroids (0.35)
and combination treatment (0.26). This effect modifica-
tion was confirmed when we tested for effect modification
formally (P = 0.46 for long-acting anticholinergics, P =
0.02 for inhaled corticosteroids, and P = 0.01 for combi-
nation treatment). Effects of long-acting anticholinergics
and combination treatment did not differ significantly
(odds ratio 0.94; 95% CI 0.80 to 1.11). There was no
effect modification when stratified for FEV1 ≤ or > 50%. In
the other stratified analyses (stratified for treatment dura-
tion of ≤ and > 6 months and ≤ and > 12 months as well
as for definition of exacerbation), we did not observe any
influence of treatment duration or the definition of exac-
erbations on (relative) treatment effects.
The random coefficient model showed very similar point
estimates and 95% CIs. Compared with the simpler logis-
tic regression model, there was very small extra variability
arising from differences of treatment effects across trials
(point estimates of interstudy variances range from 10-6 to
10-9).
Discussion and conclusion
Based on 35 trials, our analysis showed that all inhaled
drug regimens significantly reduced exacerbations but
there were no significant differences between them. Thus,
it appears that inhaled corticosteroids provide no addi-
tional value in reducing exacerbations when used concur-
rently with long-acting beta-agonists. However,
combination treatment appeared to be more effective
than beta-agonists alone in patients with low FEV1.
According to the recently published BOLD study, the prev-
alence of COPD with GOLD stage II to IV in populations
over 40 years of age is around 10%, and approximately
80% of these patients have an FEV1 ≥ 50% predictedBMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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All comparisons among inhaled drug regimens Figure 2
All comparisons among inhaled drug regimens. The forest plots show odds ratios (95% confidence intervals) indicating 
the odds of at least one exacerbation in patients with a drug treatment from the row as compared with treatment from the 
corresponding column. For example, the odds ratio of 0.91 (0.81 to 1.03) indicates that long-acting anticholinergics are more 
effective than long-acting beta-agonists, although not significantly so.
(GOLD stage II) [57]. For these patients, our study sug-
gests that single treatment with long-acting beta-agonists
or long-acting anticholinergics is not only the treatment
of choice for symptom control but also for preventing
exacerbations. Although common practice is to prescribe
inhaled corticosteroids also [58,59], our findings suggest
that these patients do not need the additional medical
therapy to reduce exacerbations.
In contrast, in patients with low FEV1 (below 40% pre-
dicted), long-acting anticholinergics appear to be the
most attractive choice. They are as effective as combina-
tion treatment in reducing exacerbations but offer advan-
tages in terms of costs and adverse effects [53]. The only
head-to-head comparison of a long-acting anticholinergic
and combination treatment, the recently published
INSPIRE study, identified outcomes in agreement with
these findings [53]. The INSPIRE study also showed no
clinically relevant differences in health-related quality of
life (< 4 points on St. Georges Respiratory Questionnaire).
A significant reduction in 2-year mortality was observed
with combination treatment (3%) compared with the
long-acting anticholinergic (6%). However, this mortality
analysis should be interpreted with caution because a
closer look at how death was ascertained in the INSPIRE
trials reveals that death was only recorded for patients
who did not withdraw from treatment (65.5% with com-
bined treatment and 58.3% with long-acting anticholiner-
gic). Thus, it appears that one third of patients did not
enter the mortality analysis. Unfortunately, little evidence
is available about the combination of long-acting anti-
cholinergics and inhaled corticosteroids; however, a
recent Canadian trial indicated that this combinationBMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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Treatment comparisons Figure 3
Treatment comparisons. Comparisons of long-acting anticholinergics, inhaled corticosteroids and the combination of long-
acting beta-agonists + inhaled corticosteroids with long-acting beta-agonists alone stratified for trials including patients with an 
FEV1 > or ≤ 40% predicted.
FEV1 > 40% predicted Odds ratio (95% CI)
Long-acting anticholinergic 0.92 (0.74-1.15)
Inhaled corticosteroid 1.10 (0.97-1.25)
Long-acting bronchodilator + 
inhaled corticosteroid
1.05 (0.91-1.21)
FEV1  40% predicted
.5 1 2
Long-acting anticholinergic 0.83 (0.71-0.98)
Inhaled corticosteroid 0.75 (0.57-1.00)
.75 1.33
Long-acting bronchodilator + 
inhaled corticosteroid
0.79 (0.67-0.93)
Favors long-acting beta- 
agonists
Favors 
other drugs
All patients
Long-acting anticholinergic 0.91 (0.81-1.03)
Inhaled corticosteroid 1.00 (0.90-1.13)
Long-acting bronchodilator + 
inhaled corticosteroid 0.93 (0.84-1.04)
Odds ratio
could be the most effective treatment for reducing exacer-
bations in patients with low FEV1 [20].
Exacerbation is not the only outcome that should inform
the decision for or against adding inhaled corticosteroids
to long-acting bronchodilators. Other outcomes should
be considered as well. A recent systematic review found no
risk reduction in terms of mortality if an inhaled steroid
was added to a long-acting bronchodilator [11]. Health-
related quality of life was statistically significantly better
after combined treatment (difference of -1.64 units on St.
Georges Respiratory Questionnaire; 95% CI -2.28 to -1)
but the effects were well under the threshold representing
a minimal important difference (4 units) [11]. Arguments
for treating COPD solely with long-acting beta-agonists
are the substantially lower costs and lower risk for adverse
effects such as pneumonia, oral candidiasis, or loss of
bone density compared with combination treatmentBMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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[11,14,53,60]. Integrating and presenting this complex
information about benefits and downsides of inhaled
drug treatments is challenging. One approach is to use
decision aids that are particularly valuable for value-sensi-
tive decisions where the balance of benefits and down-
sides is not straightforward. As the decision is, in the case
of inhaled drug treatment for COPD, only between two
treatment options (bronchodilator(s) versus combined
treatment), information about the comparisons with pla-
cebo could now be excluded for simplicity, since offering
no treatment is not in the best interest of the patient.
However, whether patients benefit from such informed
decision-making requires testing in additional trials.
Unlike previous meta-analyses based on comparisons of
inhaled drugs with placebo or, in some instances, with
another inhaled drug [4-6,11,12], we argue that the com-
parative effectiveness of available treatments are of greater
interest to physicians [7,8]. To provide estimates for this
comparative effectiveness, we used a new analytical
approach to pool evidence from all available randomized
trials. Such analyses may be, in many instances, the only
way to estimate comparative treatment effectiveness;
head-to-head comparisons are unavailable, and the sam-
ple sizes required to detect small differences are unfeasibly
large. For comparison of inhaled COPD drugs, for exam-
ple, thousands of patients are required just for the main
comparison, not even accounting for subgroup effects.
There are other approaches for indirect comparisons [16-
18]. An early and important contribution emphasized the
importance of preserving randomization [16]. However,
that proposed approach only allows for a single head-to-
head comparison and not for simultaneous comparison
of all treatments under consideration. Two other
approaches [17,18] are available, but the complexity of
their statistical methods may represent a barrier for their
application and interpretation [61]. Our approach is par-
ticularly attractive because it is transparent and easily
reproducible. The multivariable logistic regression analy-
sis allows for an analysis like that used in any randomized
trial while keeping intact the randomization of each trial.
The comparisons with placebo showed the same results as
those of the meta-analyses of the Clinical Practice Guide-
line of the American College of Physicians [6]. When the
odds ratios are transformed to relative risks [62], the effect
estimates are identical to those of a conventional meta-
analysis.
A limitation of our study is that we focused on exacerba-
tions and did not consider additional outcomes such as
health-related quality of life or mortality. When we
planned the current analyses the body of evidence on
mortality was too small to provide precise effect estimates,
even if pooled. The TORCH trial [14] published in 2007
was the first trial that was powered to assess the effects of
inhaled drugs on mortality, but even this very large trial
turned out to be too small. Therefore, we decided to post-
pone analyses on mortality to a point in time where more
data would become available. Another limitation is that
we performed only a few stratified analyses. For physi-
cians, knowing more about profile-specific effect esti-
mates would be very useful. For example, more detailed
information about risk factors for exacerbations, such as
previous exacerbations, would enhance understanding
about who benefits from the addition of inhaled corticos-
teroids. Single trials are unlikely to provide such informa-
tion because of the very large sample sizes they would
require for sufficient power to detect effect modification.
Individual patient data meta-analysis and pooled analyses
may solve this problem to some extent. However, report-
ing of such patient characteristics is highly variable, and
retrieval of individual patient data from primary studies is
challenging [63].
A limitation of any approach to pool data on exacerba-
tions is that (relative) treatment effects can only be esti-
mated adequately based on the proportion of patients
with at least one exacerbation. Analysis of exacerbation
rates expressed as mean exacerbation rates per person-year
would offer a more comprehensive use of the data and
would be less dependent on the length of follow-up.
However, such data cannot be pooled adequately without
having access to adequate and fully reported analyses that
took within- and between-patient variability in exacerba-
tions into account. But as Suissa points out, most trials are
not analyzed and reported adequately[19]. Ideally, an
individual patient data meta-analysis would be conducted
but it is very challenging to convince investigators of all
relevant trials to share their data [63]. The advantage of
using the proportion of patients with at least one exacer-
bation is the limited influence of few patients with many
exacerbations on the results. Also, physicians may be
more familiar with this format and respective estimates
for treatment effects such as odds ratios or relative risks
than with mean differences in exacerbation rates. How-
ever, there is little evidence on how effect estimates should
be presented in order to facilitate the transfer from
research into practice.
A common problem of systematic reviews in COPD is
poor reporting of clinical and spirometric characteristics
of patients enrolled in included trials. It is sometimes dif-
ficult to judge whether all patients had COPD, or if some
patients had other lung disease such as asthma. Also, there
is often no separate reporting for moderate and severe
exacerbations, although it would be informative to esti-
mate the effects of inhaled steroids stratified for the sever-
ity of exacerbations. COPD is a heterogeneous disease and
it is important that future studies provide more informa-BMC Medicine 2009, 7:2 http://www.biomedcentral.com/1741-7015/7/2
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tion about their patients, including clinical characteristics,
lung function data and also information on co-treat-
ments.
The results of our study may support physicians in select-
ing inhaled drug treatments for patients with COPD. In
general, long-acting beta-agonists or anticholinergics
appear to be the treatment of choice to reduce exacerba-
tion rates. Adding an inhaled corticosteroid does not pro-
vide additional protection from exacerbations. In patients
with low FEV1, combination treatment and long-acting
anticholinergics should be favored because they reduce
the risk for exacerbations more than single treatment with
a long-acting beta-agonist. Our analyses, together with the
existing meta-analyses that considered additional out-
comes, inform patients and physicians to balance the ben-
efits and downsides of different inhaled drug treatments
for COPD.
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